The Legacy Study.

Interventional Oncology

LEGACY Study

CANCER THERAPIES
IO SOLUTIONS PORTFOLIO
VIRTUAL EVENTS
LATEST EVIDENCE
CANCER THERAPIES
IO SOLUTIONS PORTFOLIO
VIRTUAL EVENTS
LATEST EVIDENCE
 
Interventional Radiology / Interventional Oncology / Latest Evidence / Legacy Study

 
Legacy Study.

The LEGACY study is a robust multicenter study confirming TheraSphere as a neoadjuvant or standalone therapy in treating HCC.*

Included 162 consecutive treated patients with HCC | Presented by Riad Salem, MD at CIRCE 2020.

Exceeding the Standards of Care


"We studied Y-90 in HCC patients at all stages of the disease and we found that it was either equal to or better than the current standards of care but providing a much more gentle treatment for patients. And that was enough to seal the deal."

- Riad Salem, MD an Interventional Radiologist at Northwestern Memorial Hospital

Exceeding the Standards of Care
 

Study Objective

To assess local tumor control and duration of response following treatment with Y-90 glass microspheres in patients with unrespectable solitary HCC lesions.

 

Key Study Results

Patients in the LEGACY study responded to TheraSphere treatment(s)
Overall Survival rate in patients with transplant or resection following TheraSphere at 3 years
Demonstrated rate of best response by TheraSphere

Overall Survival

(Treated population)

93% overall survival rate in patients with transplant or resection following TheraSphere at 3 years.

Tumor Response

Tumor Response

(Best Response in evaluable population, localized mRECIST)
88% demonstrated rate of best response by TheraSphere (i.e. CR, PR) by localized mRECIST.

 

Study Design:

Multi-center, single-arm, retrospective study conducted at 3 U.S. sites.** Consecutive patients meeting the eligibility criteria were treated with TheraSphere Y-90 Glass Microspheres at each site between January 2014 and December 2017.


First and Only:

  • Used highly clinically relevant criteria for localized tumor control (mRECIST)
  • Reported a median dose to perfused liver volume of 410 Gy
  • Demonstrated 100% of patients achieved CR or PR (localized mRECIST)

Key Eligibility Criteria:

Unresectable solitary lesions (≤ 8 cm); Selective, lobar, or mixed administration of Y-90 glass microspheres (TheraSphere); Treatment purpose (neoadjuvant to transplantation or resection or stand-alone treatment); Child-Pugh score A; BCLC A or BCLC C (ECOG 1); No prior liver transplantation, resection, locoregional treatment or systemic therapy; No portal vein thrombosis or extrahepatic disease.


 
Timeline
 

Primary Study Endpoints Were Met

Determined by Blinded Independent Central Review (BICR)

Objective Responsive Rate

Objective Response Rate (ORR) defined as CR or PR using localized mRECIST (defined as the response within the Y-90 glass microsphere treatment area) with confirmation of response (>4 weeks).

Duration of Response (> 6 months)

Duration of Response (DoR) using localized mRecist.

Safety: Majority of adverse events were mild and resolved without medical intervention.
Legacy

LEGACY STUDY CONCLUSION:


LEGACY is the first multicenter study to report a high median perfused volume absorbed dose of 410 Gy with TheraSphere, which resulted in an 88% best response, excellent and durable tumor control and high overall survival rate in patients with early and advanced HCC.
HCC: hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer staging system; Y-90: Yttrium-90; Gy: Gray; IQR: Interquartile Range
*Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
**University of Washington, Seattle, WA; Northwestern University, Chicago, IL; Mount Sinai Health System, New York, NY
1. Complete Response (CR) and Partial Response (PR) within the treatment area according to localized mRECIST
2. Duration of Response (DoR) According to localized mRECIST
3. Median follow-up was 29.9 months [95% CI: 24.7, 34.6]
THERASPHRER™

Perform SIRT with TheraSphere™

SIMPLICIT<sup>90</sup>Y™

SIMPLICIT90Y™

Embrace Y90
SIRT Personalised Dosimetry
Physician Education

Virtual Events

Virtual Events

View our latest virtual symposia and webinars on interventional oncology topics. 
Stay up to date

Stay up to date

Stay up to date

Receive emails about the latest interventional oncology news, innovations and events.
Top